Yesterday, the CEO of Madrigal Pharmaceuticals Inc (MDGL), Paul A. Friedman, bought shares of MDGL for $471.5K.
This recent transaction increases Paul A. Friedman’s holding in the company by 2.55% to a total of $18.27 million. In addition to Paul A. Friedman, 2 other MDGL executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Madrigal Pharmaceuticals Inc has an average volume of 156K.
Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $286.33, reflecting a 152.5% upside. Seven different firms, including Citigroup and Cowen & Co., currently also have a Buy rating on the stock.
The insider sentiment on Madrigal Pharmaceuticals Inc has been positive according to 10 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Paul A. Friedman’s trades have generated a 49.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia.
